Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Jul 20, 2022 11:49am
195 Views
Post# 34837206

As if...

As if...As if the biotechs wouldn't recover!

As if Ladenburg Thalmann didn't know that they would recover!

As if Ladenburg Thalmann doesn't, therefore, have an idea of when Bioasis can make a dash for Nasdaq!

As if Bioasis and Ladenburg Thalmann don't have a storyboard developed for Nasdaq!

As if the Cresence announcement wasn't timed as the first announcement from the Bioasis Nasdaq sroryboard, with early timing to arrange required approvals, clinical trial site selections, manufacturing of peptides, patient selections and early fundraising, all in preparation for and precursors to the full storyboard being rolled out in the weeks and months ahead!

As if we shouldn't just go with the flow for a bit longer!

As if I won't have a lot more to say about things in the weeks ahead...!

As if Bioasis shareholders won't enjoy rubbing it all in the trolls' noses...!

jd

<< Previous
Bullboard Posts
Next >>